Background: Long-term (96-week) efficacy and safety of the protease inhibitor (PI) darunavir coadministered with low-dose ritonavir (DRV/r) was evaluated in HIV type-1 (HIV-1)-infected patients with extensive prior treatment experience in the POWER 1, 2 and 3 trials. Methods: Patients with HIV-1 RNA≥1,000 copies/ml and ≥1 primary PI mutation were randomized to receive either DRV/r 600/100 mg twice daily plus an optimized background regimen (OBR), or an investigator-selected control PI (CPI) plus OBR (POWER 3 was a DRV/r 600/100 mg twice daily single-arm study). The proportion of patients with HIV-1 RNA<50 copies/ml at week 96 was assessed ( The protease inhibitor (PI) darunavir coadministered with low-dose ritonavir (DRV/r) has demonstrated efficacy and tolerability in a broad range of HIV type-1 (HIV-1)-infected patients from those who are treatment-naive and early treatment-experienced through to the highly treatment-experienced population [1] [2] [3] [4] [5] [6] [7] .
The protease inhibitor (PI) darunavir coadministered with low-dose ritonavir (DRV/r) has demonstrated efficacy and tolerability in a broad range of HIV type-1 (HIV-1)-infected patients from those who are treatment-naive and early treatment-experienced through to the highly treatment-experienced population [1] [2] [3] [4] [5] [6] [7] .
The POWER (Performance Of TMC114/r When evaluated in highly treatment-Experienced patients with PI Resistance) studies are Phase IIb, 144-week trials evaluating the efficacy and safety of DRV/r in triple-class (PI-, nucleoside reverse transcriptase inhibitor [NRTI]-and non-NRTI [NNRTI])-experienced patients [1] [2] [3] [4] [5] . POWER 1 and 2 are randomized trials comparing DRV/r with investigator-selected control PIs (CPIs). POWER 3 is an open-label analysis in a larger set of similarly experienced patients. Data from these studies up to week 48 have demonstrated excellent efficacy and tolerability in these highly treatment-Introduction experienced patients, with 45-46% of DRV/r patients achieving HIV-1 RNA<50 copies/ml in pooled POWER 1 and 2 analysis, and POWER 3 (compared with only 10% of CPI patients) [4, 5] . DRV/r 600/100 mg twice daily was generally well tolerated up to week 48 in all POWER studies, with a lower or similar rate of adverse events (AEs) compared with CPIs.
Longer-term data are needed to evaluate the sustainability of the antiviral effects observed previously with DRV/r and to confirm its continued tolerability. In this communication, we present the 96-week efficacy and safety of DRV/r 600/100 mg twice daily in the POWER 1, 2 and 3 trials.
Methods

Patient population
Inclusion and exclusion criteria have been described previously [1] [2] [3] . In brief, patients were HIV-1-infected adults with plasma HIV-1 RNA>1,000 copies/ml, prior experience of ≥1 NRTI, NNRTI and PI, and ≥1 primary PI mutation [8, 9] . All patients gave written informed consent and protocols were approved by the appropriate institutional ethics committees and/or health authorities and conducted in accordance with the Declaration of Helsinki.
Study design
POWER 1 (TMC114-C213), 2 (TMC114-C202) and 3 (TMC114-C215) are registered with ClinicalTrials. gov (numbers NCT00650832, NCT00071097 and NCT00085188, respectively). Study design has been described previously [1] [2] [3] . Briefly, POWER 1 and 2 were randomized partially-blinded controlled trials comparing DRV/r with investigator-selected CPI(s), with an initial 24-week dose-finding phase [1, 2] . Only patients receiving the DRV/r 600/100 mg twice-daily dose from baseline were included in the current analysis. POWER 3 comprised two similar non-randomized open-label trials (TMC114-C215 and -C208), with all patients receiving DRV/r 600/100 mg twice daily from baseline [3] . Only data from study TMC114-C215 were included in this pre-planned 96-week efficacy analysis. All patients in POWER 1-3 received an investigator-selected optimized background regimen (OBR) from baseline.
Efficacy and safety assessments and statistical analyses
Efficacy data for DRV/r are reported pooled for POWER 1 and 2 and separately for POWER 3, but safety data for all trials were combined to provide a more robust evaluation. Data for CPI(s) from POWER 1 and 2 were included in the present efficacy analysis but safety was not evaluable because of the high rate of treatment discontinuation, mainly as a result of virological failure.
Efficacy and safety were assessed as previously described, with further evaluations at 12-week intervals between weeks 48 and 96 [1] [2] [3] . Cumulative toxicity effects were determined by recording the incidence of AEs at 24-week intervals. Statistical analyses were conducted as previously described [1] [2] [3] .
Results
Baseline demographics and characteristics
The 96-week analysis included 467 patients who initiated treatment with DRV/r 600/100 mg twice daily in POWER 1 (n=65), POWER 2 (n=66) and POWER 3 (n=336), and 124 CPI patients. Demographics and baseline disease characteristics have been reported previously and were well balanced across treatment arms [1] [2] [3] . Overall, patients had advanced HIV-1 disease (mean HIV-1 RNA 4.59 log 10 copies/ml for DRV/r and 4.49 log 10 copies/ml for CPI; median CD4 + T-cell count 129 cells/mm 3 and 163 cells/mm 3 , respectively) and extensive prior treatment experience.
Mean duration of treatment was 90.5 weeks for DRV/r (POWER 1-3) compared with 39.8 weeks for CPI (POWER 1 and 2). At the time of the week-96 analysis, 32% of DRV/r patients had discontinued therapy compared with 87% of patients receiving CPI(s). Virological failure was the main reason for discontinuation (72% CPI and 13% DRV/r patients).
Virological response
At week 96, 39% of DRV/r patients in POWER 1 and 2 achieved HIV-1 RNA<50 copies/ml, compared with 9% for CPI patients (P<0.001; intent-to-treat, time-to-loss of virological response algorithm; Figure 1 ). The difference between treatment arms was maintained regardless of subgroup (number of primary PI mutations, enfuvirtide use in the OBR and baseline HIV-1 RNA; results not shown). Of the 45% of DRV/r patients in POWER 1 and 2 with HIV-1 RNA<50 copies/ml at week 48, 80% maintained this response to week 96. In the CPI group, 11% achieved HIV-1 RNA<50 copies/ ml at week 48, with 79% maintaining the response to week 96. In POWER 3, 42% DRV/r patients achieved HIV-1 RNA<50 copies/ml at week 96, and 86% of those with undetectable viral load at week 48 maintained this response to week 96.
Immunological response
The mean absolute CD4 + T-cell count increase from baseline to week 96 in POWER 1 and 2 was 133 cells/ mm 3 
Safety analysis
The majority of AEs that occurred in DRV/r patients in POWER 1-3 reported to week 96 were grade 1 or 2 in severity, consistent with the week 48 findings [4, 5] . The most commonly reported treatment-emergent AEs were diarrhoea, nausea, nasopharyngitis and headache ( Table 1 ). The majority of rash-related AEs were also grade 1 or 2 in severity, with the exception of one grade 3 drug-related skin eruption that led to treatment discontinuation. Grade 2-4 treatment-emergent AEs considered at least possibly related to DRV/r and observed in ≥2% of patients were diarrhoea, vomiting, nausea and headache (Table 1) .
A total of 20 (4%) patients receiving DRV/r died during the treatment period, with all deaths considered to be unrelated or doubtfully related to study medication. The overall mortality rate was 2.5 per 100 patient-years of exposure and did not increase over the treatment period. The majority of deaths (75%) occurred in patients with baseline CD4 + T-cell counts of <50 cells/mm 3 , a factor known to be associated with a higher mortality risk.
The majority of laboratory abnormalities in DRV/rtreated patients were grade 1 or 2 in severity. Mean triglyceride levels decreased over time (-0.59 mmol/l [-52.24 mg/dl] from baseline to week 96); whereas slight increases were observed for mean low-density lipoprotein (0.53 mmol/l [20.49 mg/dl]), high-density lipoprotein (0.08 mmol/l [3.09 mg/dl]), and total cholesterol (0.46 mmol/l [17.79 mg/dl]). These changes occurred mainly within the first 12 weeks of treatment. The most commonly reported grade 2-4 laboratory abnormalities, observed in ≥2% of DRV/r patients, were increased total cholesterol, increased low-density lipoprotein and increased triglycerides ( Table 1 ). The majority of treatment-emergent liver-related laboratory abnormalities of interest were of grade 1 or 2 seventy. The changes in treatment-emergent grade 2-4 laboratory parameters between baseline and week 96 were generally consistent with earlier analyses [4, 5] .
Overall, there was minimal change in the type and incidence of AEs observed over time. No cumulative toxicity effects were evident with long-term use of DRV/r 600/100 mg twice daily (Table 2) . Gastrointestinal disorders, which included diarrhoea, nausea and abdominal pain, decreased during the study (Table 2) .
Discussion
The efficacy results of the present analysis support and extend the findings of POWER 1-3 at 24 and 48 weeks [1] [2] [3] [4] [5] , and show that DRV/r 600/100 mg twice daily provides sustained virological and immunological responses in treatment-experienced patients following 96 weeks of treatment. These responses were significantly greater for DRV/r than for CPI(s) in POWER 1 and 2, with responses of a similar magnitude observed in a larger set of patients in POWER 3.
Recent Phase III studies, DUET-1, DUET-2 and BENCHMRK 1 and 2 [10] [11] [12] [13] , suggest that when DRV/r is coadministered with newer antiretroviral drugs, virological response could be further enhanced in highly treatment-experienced patients. This approach is in line with current treatment guidelines for this group of patients, recommending the use of at least two fully active drugs with an OBR [14] .
AE or laboratory abnormality type
Incidence in DRV/r-treated patients, n (%) Darunavir with low-dose ritonavir (DRV/r) 600/100 mg twice daily. Total n=467. a All rash-related adverse events (AEs) were grade 1 or 2 in severity, except for one case of grade 3 drug-related skin eruption, which led to permanent treatment discontinuation. Excluding laboratory abnormalities reported as AEs. ALP, alkaline phosphatise; ALT, alanine aminotransferase; AST, aspartate aminotransferase; LDL, low-density lipoprotein.
The long-term safety and tolerability of antiretroviral therapies are of particular importance. A robust comparison of safety data between DRV/r and CPI was not possible in this study at 96 weeks because of high levels of treatment discontinuation in CPI patients in POWER 1 and 2. However, the type and incidence of AEs in the DRV/r arms were consistent across POWER 1-3 studies at 24, 48 and 96 weeks [1] [2] [3] [4] [5] . Indeed, the majority of AEs reported in this 96-week analysis were grade 1 or 2 in severity, with DRV/r 600/100 mg twice daily generally very well tolerated by patients, and with no new safety concerns identified.
In conclusion, these data support the use of DRV/r 600/100 mg twice daily for robust, long-term treatment of patients with advanced HIV-1 infection and extensive prior antiretroviral experience. As new agents become available, greater and more durable viral suppression can be expected, helping more patients with multidrug-resistant HIV-1 infections to reach undetectable HIV-1 RNA and to achieve longterm treatment success.
